Feedback / Questions
vedolizumab subcutaneous (CLS-001) - Comera Life Sci
https://www.globenewswire.com/news-release/2022/11/10/2553162/0/en/Comera-Life-Sciences-Reports-Financial-Results-for-Third-Quarter-2022-and-Business-Highlights.html
Nov 10, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev